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EDITORIAL
HIGH SPECIFICITY MAKES
DNA SCREENING THE METHOD
OF CHOICE FOR DIAGNOSIS
OF FAMILIAL HYPER-
CHOLESTEROLAEMIA
The diagnosis of familial hypercholesterolaemia (PH) is based
on clinical findings, a family history of premature
atherosclerosis and elevated plasma cholesterol levels.'
Identification of heterozygous PH is complicated by the fact
that biochemical parameters may overlap between normal and
affected individuals, especially in children! and most adult
patients do not present with cholesterol deposits in the skin
and tendons. The importance of a DNA test that can provide a
simple yes/no answer has now been demonstrated clearly in'
the article by Vergotine and colleagues in this issue of the
Journal.3 Mutation screening of the low-density lipoprotein
receptor (LDLR) gene in more than 1 000 subjects has shown
that 15.6% of at-risk family members may be misdiagnosed
when total cholesterol (TC) concentration at the 80th percentile
for age and gender is used as a biochemical cut-off point for a
diagnosis of PH, compared with 12.4% using the 95th
percentile. The sensitivity and specificity of PH diagnosis
according to TC values (80th percentile) were shown to be
89.3% and 81.9%, respectively.
The main advantage of DNA testing for PH is its very high
specificity compared with clinical criteria. Specificity of a test is
defined as the ability to identify positively only those
individuals who have the disease, in order to avoid treatment
of unaffected individuals. The test should also be sensitive
enough to avoid missing the diagnosis and subsequent
treatment of affected individuals. Recent surveys have shown
that the majority of the estimated 10 million people affected
with PH worldwide are undiagnosed, untreated or poorly
treated. Only a small percentage (-2.5%) of the estimated
120000 PH heterozygotes in South Africa have been identified
and of the expected 200 homozygotes, less than 100 patients
have been diagnosed as having PH.'
To date, more than 700 LDLR gene mutations underlying PH
have been identified worldwide (http://www.ucl.ac.uk/fh;
http://umd.necker.fr), which complicates D A diagnosis.
However, in the South African population where a small
number of disease-related mutations predominate,'" mostly
owing to founder effects and/or multiple entries of defective
genes into the local population, cost-effective D A diagnosis is
possible. The issue of costs involved in DNA screening is
becoming increasingly important in health care systems and
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therefore it is advantageous that a DNA test needs to be done
only once in a lifetime.
The question may be asked why it is important to
distinguish PH from other types of hyperlipidaemias. The mair
reason is that PH patients have a significantly higher risk of
coronary heart disease compared with other
hypercholesterolaemics in the general population, and PH
requires more aggressive treatment. Coronary deaths occur in
50% of men by the age of 60 years (75% present with coronary
symptoms) and only 20% reach the age of 70 years. In women
these figures are 15% (45% present with corQnary symptoms)
and 70%, respectively (Report on a World Health Organisation
Consultation on Familial Hypercholesterolaemia, Paris, 3
October 1997). A DNA test for PH furthermore provides a
definitive tool for family tracing, allowing accurate disease
diagnosis in approximately half of the relatives analysed and
consequently preventive treatment.'D Since most people are in
favour of family screening for treatable genetic diseases like
PH," programmes for systematic DNA screening should be
encouraged. However, in order to limit negative reactions the
diagnosis should be accompanied by individual counselling on
risk and treatment possibilities. Patients should be informed of
ethical issues before genetic testing and give their full consent,'
especially since the identification of an PH-related mutation
would affect other relati~eswho should be made aware of the
availability of a genetic test for accurate disease diagnosis in
the family.
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